Vertex Pharmaceuticals Incorporated (VRTX) Free Cash Flow CAGR:2.42%(TTM)
The free cash flow cagr for Vertex Pharmaceuticals Incorporated (VRTX) is +2.42% over the latest trailing 12-month period. Free cash flow CAGR uses precomputed cash-flow statement history.
The free cash flow cagr for Vertex Pharmaceuticals Incorporated (VRTX) stock is 2.42% over the past 12 months. The 3 year average growth rate is -1.57% and the 5 year cagr is 4.01%. Free cash flow CAGR measures how Vertex Pharmaceuticals Incorporated's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
VRTX Free Cash Flow CAGR Chart
Vertex Pharmaceuticals Incorporated (VRTX)
VRTX Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $-790.30M | $3.19B | +$3.98B | +0.00% | N/A |
| 2024 | $3.28B | $-790.30M | $-4.07B | -124.10% | N/A |
| 2023 | $3.93B | $3.28B | $-646.30M | -16.47% | -16.47% |
| 2022 | $2.41B | $3.93B | +$1.52B | +62.97% | +62.97% |
| 2021 | $2.99B | $2.41B | $-585.21M | -19.55% | -19.55% |
| 2020 | $1.49B | $2.99B | +$1.50B | +100.40% | +100.40% |
| 2019 | $1.17B | $1.49B | +$319.12M | +27.16% | +27.16% |
| 2018 | $585.52M | $1.17B | +$589.24M | +100.64% | +100.64% |
| 2017 | $179.54M | $585.52M | +$405.98M | +226.12% | +226.12% |
| 2016 | $-410.73M | $179.54M | +$590.27M | +0.00% | N/A |
| 2015 | $-564.40M | $-410.73M | +$153.67M | +0.00% | N/A |
| 2014 | $-102.96M | $-564.40M | $-461.44M | +0.00% | N/A |
| 2013 | $196.70M | $-102.96M | $-299.66M | -152.34% | N/A |
| 2012 | $49.14M | $196.70M | +$147.56M | +300.29% | +300.29% |
| 2011 | $-673.50M | $49.14M | +$722.64M | +0.00% | N/A |
| 2010 | $-451.08M | $-673.50M | $-222.41M | +0.00% | N/A |
| 2009 | $-258.66M | $-451.08M | $-192.42M | +0.00% | N/A |
| 2008 | $-284.89M | $-258.66M | +$26.23M | +0.00% | N/A |
| 2007 | $-54.89M | $-284.89M | $-230.00M | +0.00% | N/A |
| 2006 | $-189.01M | $-54.89M | +$134.12M | +0.00% | N/A |
| 2005 | $-154.66M | $-189.01M | $-34.36M | +0.00% | N/A |
| 2004 | $-184.97M | $-154.66M | +$30.32M | +0.00% | N/A |
| 2003 | $-120.76M | $-184.97M | $-64.22M | +0.00% | N/A |
| 2002 | $-61.97M | $-120.76M | $-58.78M | +0.00% | N/A |
| 2001 | $-28.56M | $-61.97M | $-33.42M | +0.00% | N/A |
| 2000 | $-48.00M | $-28.56M | +$19.44M | +0.00% | N/A |
| 1999 | $-39.00M | $-48.00M | $-9.00M | +0.00% | N/A |
| 1998 | $-15.40M | $-39.00M | $-23.60M | +0.00% | N/A |
| 1997 | $-44.30M | $-15.40M | +$28.90M | +0.00% | N/A |
Quarterly Free Cash Flow — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $1.29B | +271.4% | +66.4% |
| Q4 2025 | $348.60M | -69.4% | -29.1% |
| Q3 2025 | $1.14B | +22.9% | -12.5% |
| Q2 2025 | $927.40M | +19.2% | +124.2% |
| Q1 2025 | $778.20M | +58.2% | -26.5% |
| Q4 2024 | $492.00M | -62.2% | +178.8% |
| Q3 2024 | $1.30B | +134.0% | +6.1% |
| Q2 2024 | -$3.83B | -462.0% | -456.4% |
| Q1 2024 | $1.06B | +499.5% | +23.4% |
| Q4 2023 | $176.50M | -85.6% | -83.1% |
| Q3 2023 | $1.23B | +14.2% | +36.2% |
| Q2 2023 | $1.07B | +25.3% | -1.1% |
| Q1 2023 | $857.80M | -17.9% | -3.9% |
| Q4 2022 | $1.04B | +15.9% | +12.0% |
| Q3 2022 | $901.30M | -17.0% | +3.0% |
| Q2 2022 | $1.09B | +21.7% | +535.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani